PTCT PTC Therapeutics, Inc.
Stock · NasdaqGS · United States · Healthcare · US69366J2006
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by PTC Therapeutics, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
65.44 USD
-0.35%
52-week range
58.80 – 90.87
Dividend yield—
Market cap5.5B
NowoTrade score
53 Grade A
Price history
Daily prices in USD.
Updated 07 Nov 2026 09:45. Information, not advice.
Results
Next results
18 Feb 2027
in 103 days · 16:00 · estimate 0.24
Last results
-0.39 vs 0.27 estimated
29 Oct 2026 · Miss -243.9%
Beat the estimate
7 of 12
5 missed · 0 in line
Average surprise
+102.5%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 18 Feb 2027 16:00 | 0.24 | — | — | Upcoming |
| 29 Oct 2026 16:00 | 0.27 | -0.39 | -243.9% | Miss |
| 30 Jul 2026 16:00 | 0.34 | 0.92 | +170.6% | Beat |
| 07 May 2026 16:00 | -0.44 | -0.03 | +93.2% | Beat |
| 19 Feb 2026 16:00 | -0.40 | -1.80 | -343.5% | Miss |
| 04 Nov 2025 16:00 | -1.11 | 0.19 | +116.9% | Beat |
| 07 Aug 2025 16:00 | -1.06 | -0.83 | +21.9% | Beat |
| 06 May 2025 16:00 | -0.70 | 10.04 | +1,524.1% | Beat |
| 27 Feb 2025 16:00 | -0.65 | -0.34 | +47.5% | Beat |
| 07 Nov 2024 16:00 | -1.66 | -1.36 | +17.8% | Beat |
| 08 Aug 2024 16:00 | -0.95 | -1.27 | -33.7% | Miss |
| 25 Apr 2024 16:00 | -1.10 | -1.20 | -9.1% | Miss |
| 29 Feb 2024 16:00 | 0.92 | -0.29 | -131.9% | Miss |
| 26 Oct 2023 16:00 | -1.55 | -1.75 | -12.8% | Miss |
| 03 Aug 2023 16:00 | -1.71 | -1.58 | +7.7% | Beat |
| 27 Apr 2023 16:00 | -1.63 | -1.88 | -15.1% | Miss |
| 21 Feb 2023 16:00 | -1.74 | -1.94 | -11.5% | Miss |
| 27 Oct 2022 16:00 | -1.26 | -1.53 | -21.2% | Miss |
| 04 Aug 2022 16:00 | -1.48 | -2.13 | -43.6% | Miss |
| 03 May 2022 16:00 | -1.66 | -1.78 | -7.4% | Miss |
| 22 Feb 2022 16:00 | -1.55 | -2.03 | -30.6% | Miss |
| 28 Oct 2021 16:00 | -1.89 | -1.89 | 0.0% | In line |
| 29 Jul 2021 16:00 | -1.82 | -1.68 | +7.6% | Beat |
| 04 May 2021 16:00 | -1.62 | -1.83 | -12.7% | Miss |
| 25 Feb 2021 16:00 | -0.90 | -1.08 | -19.9% | Miss |
| 29 Oct 2020 16:00 | -0.45 | -1.03 | -130.1% | Miss |
| 05 Aug 2020 16:00 | -1.56 | -1.80 | -15.3% | Miss |
| 30 Apr 2020 17:00 | -1.40 | -1.81 | -29.3% | Miss |
| 02 Mar 2020 16:00 | -0.71 | -1.37 | -93.0% | Miss |
| 29 Oct 2019 16:00 | -0.88 | -0.89 | -1.9% | Miss |
| 06 Aug 2019 16:00 | -0.61 | -0.65 | -6.6% | Miss |
| 02 May 2019 16:00 | -0.68 | -0.91 | -33.8% | Miss |
| 28 Feb 2019 16:00 | -0.38 | -0.58 | -55.6% | Miss |
| 05 Nov 2018 16:00 | -0.49 | -1.06 | -115.8% | Miss |
| 07 Aug 2018 16:00 | -0.44 | -0.21 | +52.2% | Beat |
| 09 May 2018 16:00 | -0.38 | -0.46 | -22.1% | Miss |
| 06 Mar 2018 16:00 | -0.05 | 0.03 | +161.7% | Beat |
| 02 Nov 2017 16:00 | -0.67 | -0.82 | -22.4% | Miss |
| 08 Aug 2017 16:00 | -0.86 | -0.44 | +48.6% | Beat |
| 08 May 2017 07:00 | -0.93 | -0.85 | +8.2% | Beat |
| 16 Mar 2017 07:00 | -1.02 | -0.78 | +23.2% | Beat |
| 02 Nov 2016 16:00 | -1.15 | -1.03 | +10.3% | Beat |
| 04 Aug 2016 16:00 | -1.24 | -1.14 | +8.4% | Beat |
| 05 May 2016 16:00 | -1.25 | -1.22 | +2.5% | Beat |
| 29 Feb 2016 16:00 | -1.20 | -1.50 | -24.8% | Miss |
| 09 Nov 2015 16:00 | -1.11 | -1.27 | -14.1% | Miss |
| 30 Jul 2015 16:00 | -1.20 | -1.14 | +4.9% | Beat |
| 04 May 2015 16:00 | -1.17 | -1.15 | +1.8% | Beat |
| 27 Feb 2015 08:00 | -0.75 | -0.84 | -11.5% | Miss |
| 06 Nov 2014 08:00 | -0.94 | -0.93 | +1.3% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 1.7B | +114.5% | 682.6M | 39.4% | 7.78 | +264.5% | 411.2M |
| 2024 | 806.8M | -14.0% | -363.3M | -45.0% | -4.73 | +43.5% | -181.9M |
| 2023 | 937.8M | +34.2% | -626.6M | -66.8% | -8.37 | -7.4% | -279M |
| 2022 | 698.8M | — | -559M | -80.0% | -7.79 | — | -509.1M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 06 Nov 2026 | 65.99 | 66.67 | 65.15 | 65.44 | -0.35% | 898,800 | |
| 05 Nov 2026 | 68.80 | 69.59 | 65.45 | 65.67 | -4.78% | 1,238,400 | |
| 04 Nov 2026 | 69.68 | 70.11 | 66.87 | 68.97 | +1.25% | 1,343,600 | |
| 03 Nov 2026 | 64.14 | 68.72 | 63.16 | 68.12 | +11.89% | 2,643,700 | |
| 02 Nov 2026 | 61.05 | 62.16 | 59.16 | 60.88 | +1.52% | 1,339,300 | |
| 30 Oct 2026 | 64.75 | 65.34 | 59.64 | 59.97 | -6.97% | 2,357,600 | |
| 29 Oct 2026 | 63.51 | 65.00 | 63.51 | 64.46 | +2.28% | 1,524,200 | |
| 28 Oct 2026 | 61.82 | 63.11 | 61.00 | 63.02 | +1.50% | 909,200 | |
| 27 Oct 2026 | 61.07 | 62.31 | 59.87 | 62.09 | +1.67% | 1,117,100 | |
| 26 Oct 2026 | 60.84 | 61.85 | 60.46 | 61.07 | +0.79% | 708,800 | |
| 23 Oct 2026 | 62.30 | 63.49 | 59.97 | 60.59 | -3.89% | 674,200 | |
| 22 Oct 2026 | 62.62 | 63.49 | 62.24 | 63.04 | +0.67% | 675,400 | |
| 21 Oct 2026 | 63.14 | 63.74 | 62.41 | 62.62 | -0.48% | 944,200 | |
| 20 Oct 2026 | 62.27 | 63.24 | 61.58 | 62.92 | +2.26% | 965,800 | |
| 19 Oct 2026 | 60.13 | 61.74 | 59.35 | 61.53 | +3.87% | 944,000 | |
| 16 Oct 2026 | 61.08 | 61.73 | 58.98 | 59.24 | -2.87% | 789,000 | |
| 15 Oct 2026 | 61.08 | 62.31 | 59.88 | 60.99 | +2.21% | 1,051,900 | |
| 14 Oct 2026 | 59.30 | 60.69 | 58.80 | 59.67 | -0.42% | 1,519,800 | |
| 13 Oct 2026 | 62.64 | 62.75 | 59.82 | 59.92 | -4.77% | 1,051,400 | |
| 12 Oct 2026 | 64.80 | 65.03 | 62.88 | 62.92 | -2.75% | 745,200 | |
| 09 Oct 2026 | 62.52 | 64.73 | 62.20 | 64.70 | +3.42% | 1,171,200 | |
| 08 Oct 2026 | 62.66 | 62.86 | 61.65 | 62.56 | -1.06% | 1,227,500 | |
| 07 Oct 2026 | 63.19 | 64.04 | 62.84 | 63.23 | -0.74% | 1,040,500 | |
| 06 Oct 2026 | 64.53 | 65.27 | 62.92 | 63.70 | +0.08% | 1,265,000 | |
| 05 Oct 2026 | 63.42 | 64.47 | 62.60 | 63.65 | +0.30% | 1,044,000 |
Page 1 of 51
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Former Biopharma Execs Lists Florida Compound With Rooftop Pool for $64 Million (opens in a new tab) The Wall Street Journal · 03 Nov 2026 21:30
- PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program (opens in a new tab) 03 Nov 2026 12:00
- PTC Therapeutics: Sephience Keeps Beating The Forecast, But The Price Already Knows (opens in a new tab) SeekingAlpha · 03 Nov 2026 11:31
- PTC Therapeutics Board Authorizes $500M Share Repurchase Program (opens in a new tab) Benzinga · 03 Nov 2026 08:02
- Citigroup Maintains Buy on PTC Therapeutics, Raises Price Target to $109 (opens in a new tab) Benzinga · 02 Nov 2026 14:41
- PTC Therapeutics to Participate in Upcoming Investor Conferences (opens in a new tab) 02 Nov 2026 13:00
- PTC Therapeutics (PTCT) Stock Slides As Q3 Results Return To Loss (opens in a new tab) Simply Wall St. · 31 Oct 2026 17:12
- PTC Therapeutics (PTCT) Lifts Guidance As Fair Value Stays In Focus (opens in a new tab) Simply Wall St. · 30 Oct 2026 23:17
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (opens in a new tab) 30 Oct 2026 20:30
- TD Cowen Maintains Buy on PTC Therapeutics, Raises Price Target to $95 (opens in a new tab) Benzinga · 30 Oct 2026 16:07
- PTC Therapeutics (PTCT) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 30 Oct 2026 15:00
- RBC Capital Maintains Sector Perform on PTC Therapeutics, Raises Price Target to $77 (opens in a new tab) Benzinga · 30 Oct 2026 12:56
- Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $112 (opens in a new tab) Benzinga · 30 Oct 2026 12:56
- PTC Therapeutics, Inc. Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 30 Oct 2026 12:30
- PTC Therapeutics Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 30 Oct 2026 01:14
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 65.67 USD
- Market cap
- 5.5B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 | — |
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 15.3 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 7.2 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
- Total debt has risen three years in a row
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 6 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | 26.93× | Weak | 14.98× |
| Price / book | -28.59× | Weak | 3.94× |
| Price / sales | 4.73× | Fair | 3.37× |
| EV / EBITDA | 20.35× | Weak | 12.96× |
| Free cash flow yield | 2.9% | Fair | 2.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 55.2% | Good | 59.2% |
| Operating margin | 38% | Good | 7.4% |
| Net margin | -9.2% | Weak | 3.4% |
| Return on assets | 5.3% | Fair | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 35.3% | Good | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | -13.19× | Good | 0.46× |
| Net debt / EBITDA | 2.63× | Fair | 1.5× |
| Interest cover | 5.63× | Fair | 3.26× |
| Current ratio | 3.27× | Good | 2.35× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow PTCT and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.